There are reasons to be optimistic over the cutting-edge mRNA vaccines being developed to end the COVID-19 pandemic, according to an expert in the field.
Pfizer is to pay German company BioNTech up to $425m for a multi-year collaboration in the development of more effective influenza vaccines, joining other pharma giants in a promising mRNA-
